Arcutis Biotherapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARQT research report →
About the company
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis.
- CEO
- Todd Franklin Watanabe
- IPO
- 2020
- Employees
- 354
- HQ
- Westlake Village, CA, US
Price Chart
Get TickerSpark's AI analysis on ARQT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $3.44B
- P/E
- -1433.85
- P/S
- 8.29
- P/B
- 18.78
- EV/EBITDA
- 234.46
- Div Yield
- 0.00%
- Gross Margin
- 90.94%
- Op Margin
- 0.77%
- Net Margin
- -0.57%
- ROE
- -1.41%
- ROIC
- 1.05%
- Revenue
- $376.07M · 91.34%
- Net Income
- $-16,140,999 · 88.47%
- EPS
- $-0.13 · 88.79%
- Op Income
- $-12,227,000
- FCF YoY
- 94.38%
- 52W High
- $31.77
- 52W Low
- $13.70
- 50D MA
- $24.04
- 200D MA
- $24.93
- Beta
- 1.48
- Avg Volume
- 1.81M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 15, 26 | Peetz Christopher | other | 21,486 |
| Jul 15, 26 | Peetz Christopher | other | 13,010 |
| Jul 15, 26 | Peetz Christopher | other | 4,315 |
| Jul 15, 26 | Peetz Christopher | other | 0 |
| Jul 15, 26 | Welgus Howard G. | other | 2,255 |
| Jul 15, 26 | Welgus Howard G. | other | 1,019 |
| Jul 15, 26 | Welgus Howard G. | other | 822 |
| Jul 15, 26 | Welgus Howard G. | sell | 4,730 |
| Jul 15, 26 | Welgus Howard G. | other | 2,255 |
| Jul 15, 26 | Welgus Howard G. | other | 1,019 |
Our ARQT coverage
Recent articles, reports, and earnings notes.
Want a deeper read on ARQT?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.
Arcutis Expands Board of Directors with Appointment of Chris Peetz
globenewswire.com · Jul 16
Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
globenewswire.com · Jul 15
Biotech Stock Arcutis Climbs Into Buy Zone As FDA Mulls Expanded Use For Key Skin Treatment
investors.com · Jul 9
FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
globenewswire.com · Jul 8
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?
fool.com · Jul 3
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Jul 2
Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications
globenewswire.com · Jun 30
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
globenewswire.com · Jun 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
Community Sentiment
Be the first to call it — is ARQT a buy or a sell from here?